On July 16th, Genetic Analysis AS (”Genetic Analysis” or the ”Company”) announced the publication of a peer-reviewed study in the scientific journal Gut Microbes, demonstrating that the GA-map® Dysbiosis Test delivers consistent results across geographically diverse populations. The findings address population variability, one of the challenges in microbiome diagnostics, and support the broader international applicability of the GA-map® platform.
In summary, Analyst Group views the publication as a scientifically credible validation that reinforces the standardization narrative at the heart of the Company’s investment case. By evidencing consistent diagnostic performance across geographically diverse populations, the study supports the broader international applicability of the GA-map® platform and is expected to strengthen both laboratory adoption and partner-facing opportunities over time, though the impact is expected to accrue gradually rather than immediately.
Read Analyst Group’s comment here
About Analyst Group: One of Sweden's leading equity research boutiques with focus on small and medium-sized listed companies.
Read more about Analyst Group
This is a press release from Analyst Group regarding the publication of a comment on Genetic Analysis. Readers may assume that Analyst Group has received compensation for making the comment. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.